Drug Type Synthetic peptide |
Synonyms MT 1013, MT1013 |
Target |
Mechanism PTH1R antagonists(Parathyroid hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperparathyroidism, Secondary | Phase 2 | CN | 07 Apr 2023 | |
Hypercalcemia | Phase 2 | US | - | |
Hypercalcemia | Phase 2 | CN | - | |
Nephrosis | Phase 1 | CN | 29 Dec 2021 |